Telomir Pharmaceuticals, Inc. announced on July 23, 2025, positive preclinical results for its lead compound, Telomir-1, which shows potential in restoring mitochondrial function without causing harmful cell division, particularly in cells affected by Hutchinson-Gilford Progeria Syndrome.